Research programme: complement factor 5a inhibitors - Evolutec

Drug Profile

Research programme: complement factor 5a inhibitors - Evolutec

Latest Information Update: 19 Mar 2008

Price : $50

At a glance

  • Originator Evolutec
  • Developer Case Western Reserve University; Evolutec
  • Class Recombinant proteins
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Autoimmune disorders; Guillain-Barre syndrome; Inflammation; Myasthenia gravis; Reperfusion injury

Most Recent Events

  • 31 Oct 2006 Preclinical trials in Asthma in United Kingdom (Parenteral)
  • 31 Oct 2006 Preclinical trials in Guillain-Barre syndrome in United Kingdom (Parenteral)
  • 29 May 2006 Case Western Reserve University has entered into an agreement with Evolutec to conduct further preclinical stuides of rEV 576 for myasthenia gravis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top